I fear that the issue of efficacy/engraftment may beccome a serious matter.
We've had little to no feedback from the company recently, nor for months on the clinical patient's blogs. That's disturbing.
Clearly no time to buy and , imo, one needs to wait for some feedback on the 100, 000stem cell patients and that's months away.
Couple that with the expiring proxy approval soon, coupled with outstanding legal matter that must be settled before uplisting and buying now is clearly folly, imo, as we clearly are going lower.